Pathway changes of MV4-11 after treatment with HDL NPs. (A) Top 10 DEGs from bulk RNA sequencing analysis. (B) Top pathways that are enhanced from pathway analysis from DEGs. (C) Mature granulocyte surface marker staining of CD11c, CD14, and CD24 of MV4-11 after HDL NP treatment from 1 to 10 nM. ∗∗P < .01; ∗∗∗P < .01; ∗∗∗∗P < .0001.